Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MacKenzie Feder, Jessica; Bourdeau, Isabelle; Vallette, Sophie; Beauregard, Hugues; Ste-Marie, Louis-Georges; Lacroix, André.
; 17(6): 519-29, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24287689
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.
SOM230: a new therapeutic modality for Cushing's disease.
Emerging drugs for acromegaly.
A 12-month phase 3 study of pasireotide in Cushing's disease.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
Biochemical efficacy of long-acting lanreotide depot/Autogel in patients with acromegaly naïve to somatostatin-receptor ligands: analysis of three multicenter clinical trials.
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.